Arena Pharmaceuticals News

The Food and Drug Administration approved the weight-loss therapy Belviq from Arena Pharmaceuticals, Inc.

A sharp drop in Arena Pharmaceuticals followed after the company reported quarterly earnings and a withdrawal of its Marketing Authorization Application in the EU.

In this video, health-care analyst David Williamson looks at Vivus ' first-quarter results and breaks it down into key takeaways for investors in both Vivus and its competitor Arena .

Arena Pharmaceuticals has now received its long anticipated scheduling for Belviq from the DEA , and its fate in Europe , at least in the short-term, is a known for investors.

A live audio webcast of the presentation will be available under the investor relations section of Arena's website at www.arenapharm.com . A replay of the presentation will be available for 30 days following the event.

Arena Pharmaceuticals' Belviq, the weight-loss pill approved in June by the Food and Drug Administration, was cleared to start sales next month after a separate review found the drug's abuse potential to be low.

The scheduling designation will be effective 30 days after tomorrow's expected publication in the Federal Register.

As a leading provider of free in depth reports and timely market updates, Paragon is an essential resource for hundreds of thousands of investors across the country.

The number of bullish hedge fund positions inched up by 3 lately. At the moment, there are dozens of gauges shareholders can use to track stocks.

Responding to news that the company would withdraw its MAA for Belviq from the EMA, shares of Arena Pharmaceuticals tanked by 9.2% last Friday as investors questioned whether obesity drugs had a future in the EU market.

Other equities research analysts have also recently issued reports about the stock.

Arena Pharmaceuticals had a rough quarter, but the results don't really matter. The company is waiting on DEA scheduling before it can start selling its obesity drug, Belviq.

Give yourself an advantage in today's market. In order to become successful, you need to have information as it happens and understand how it plays out into future stock price.

Arena Pharmaceuticals Inc. said Thursday that its loss narrowed in the first quarter, though company executives said they are still waiting for a federal decision on the status of the weight loss drug Belviq.

Check below for free stories on AIG;ARNA;PKT;DDD;SPLS;DCTH;YRCW;INVN;WTW;BBRY;SKUL the last two weeks.

Midway through trading Friday, the Dow traded up 1.04 percent to 14,985.73 while the NASDAQ surged 1.29 percent to 3,383.74. The S&P also rose, gaining 1.13 percent to 1,615.66. LinkedIn posted its first-quarter earnings at $22.6 million, or $0.20 per share, versus $5 million, or $0.04 per share, in the year-ago period.

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today! SAN DIEGO, May 2, 2013 /PRNewswire via COMTEX/ -- Arena Pharmaceuticals, Inc.

Welcome, ladies and gentlemen and welcome to the Arena Pharmaceuticals first quarter 2013 financial results call.

Arena Pharmaceuticals Inc. , the maker of the weight-loss drug Belviq, said it is withdrawing its application to gain regulatory approval in Europe for the obesity medicine.

Investing in biotech companies can be intimidating, especially for investors without a science background.